{"id":"https://openalex.org/W4416627366","doi":"https://doi.org/10.1158/1078-0432.30706293","title":"Supplementary Table S1 from Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies","display_name":"Supplementary Table S1 from Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies","publication_year":2025,"publication_date":"2025-11-25","ids":{"openalex":"https://openalex.org/W4416627366","doi":"https://doi.org/10.1158/1078-0432.30706293"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.30706293","doi":"https://doi.org/10.1158/1078-0432.30706293","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30706293","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Lisaftoclax_in_Combination_with_Alrizomadlin_Overcomes_Venetoclax_Resistance_in_Acute_Myeloid_Leukemia_and_Acute_Lymphoblastic_Leukemia_Preclinical_Studies/30706293/1/files/59830674.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Lisaftoclax_in_Combination_with_Alrizomadlin_Overcomes_Venetoclax_Resistance_in_Acute_Myeloid_Leukemia_and_Acute_Lymphoblastic_Leukemia_Preclinical_Studies/30706293/1/files/59830674.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021773274","display_name":"Yifan Zhai","orcid":"https://orcid.org/0000-0003-1672-2262","observed_orcids":["https://orcid.org/0000-0003-1672-2262"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yifan Zhai","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1672-2262","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110047891","display_name":"Qiuqiong Tang","orcid":"https://orcid.org/0000-0002-9164-6290","observed_orcids":["https://orcid.org/0000-0002-9164-6290"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qiuqiong Tang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9164-6290","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074334301","display_name":"Douglas D. Fang","orcid":"https://orcid.org/0000-0002-0895-332X","observed_orcids":["https://orcid.org/0000-0002-0895-332X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Douglas D. Fang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0895-332X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065668271","display_name":"Jing Deng","orcid":"https://orcid.org/0000-0003-3157-5723","observed_orcids":["https://orcid.org/0000-0003-3157-5723"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jing Deng","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3157-5723","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022301199","display_name":"Kaixiang Zhang","orcid":"https://orcid.org/0000-0002-3666-8868","observed_orcids":["https://orcid.org/0000-0002-3666-8868"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kaixiang Zhang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3666-8868","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053150001","display_name":"Qixin Wang","orcid":"https://orcid.org/0000-0003-1525-4540","observed_orcids":["https://orcid.org/0000-0003-1525-4540"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qixin Wang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1525-4540","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028456330","display_name":"Yan Yin","orcid":"https://orcid.org/0000-0003-1563-4666","observed_orcids":["https://orcid.org/0000-0003-1563-4666"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yan Yin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1563-4666","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051994266","display_name":"Chengcheng Fu","orcid":"https://orcid.org/0000-0001-8623-848X","observed_orcids":["https://orcid.org/0000-0001-8623-848X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chengcheng Fu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8623-848X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027546968","display_name":"Shengli Xue","orcid":"https://orcid.org/0000-0003-4609-616X","observed_orcids":["https://orcid.org/0000-0003-4609-616X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sheng-Li Xue","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4609-616X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028312727","display_name":"Na Li","orcid":"https://orcid.org/0000-0001-5930-412X","observed_orcids":["https://orcid.org/0000-0001-5930-412X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Na Li","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5930-412X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077134386","display_name":"Feng Zhou","orcid":"https://orcid.org/0000-0002-9034-7109","observed_orcids":["https://orcid.org/0000-0002-9034-7109"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Feng Zhou","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9034-7109","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5085723739","display_name":"Dajun Yang","orcid":"https://orcid.org/0000-0002-6027-3604","observed_orcids":["https://orcid.org/0000-0002-6027-3604"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dajun Yang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6027-3604","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venetoclax-resistance","display_name":"venetoclax resistance","score":0.9940000176429749},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9750000238418579},{"id":"https://openalex.org/keywords/acute-lymphoblastic-leukemia","display_name":"acute lymphoblastic leukemia","score":0.9929999709129333},{"id":"https://openalex.org/keywords/relapsed-refractory-leukemia","display_name":"relapsed/refractory leukemia","score":0.9649999737739563},{"id":"https://openalex.org/keywords/clinical-characteristics","display_name":"clinical features","score":0.8420000076293945}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8659999966621399},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.8076000213623047},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7307999730110168},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5242000222206116},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49239999055862427},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.476500004529953},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.46959999203681946},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.3930000066757202},{"id":"https://openalex.org/C2909962599","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic Leukemia","level":3,"score":0.3504999876022339},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3456000089645386},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.33169999718666077},{"id":"https://openalex.org/C45235069","wikidata":"https://www.wikidata.org/wiki/Q278425","display_name":"Table (database)","level":2,"score":0.3228999972343445},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.3131999969482422},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.31029999256134033},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.3043000102043152},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3041999936103821},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.29260000586509705},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.28290000557899475},{"id":"https://openalex.org/C2781107101","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Acute lymphocytic leukemia","level":4,"score":0.2678999900817871}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.30706293","doi":"https://doi.org/10.1158/1078-0432.30706293","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30706293","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Lisaftoclax_in_Combination_with_Alrizomadlin_Overcomes_Venetoclax_Resistance_in_Acute_Myeloid_Leukemia_and_Acute_Lymphoblastic_Leukemia_Preclinical_Studies/30706293/1/files/59830674.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/30706293","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Lisaftoclax_in_Combination_with_Alrizomadlin_Overcomes_Venetoclax_Resistance_in_Acute_Myeloid_Leukemia_and_Acute_Lymphoblastic_Leukemia_Preclinical_Studies/30706293","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.30706293","doi":"https://doi.org/10.1158/1078-0432.30706293","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30706293","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Lisaftoclax_in_Combination_with_Alrizomadlin_Overcomes_Venetoclax_Resistance_in_Acute_Myeloid_Leukemia_and_Acute_Lymphoblastic_Leukemia_Preclinical_Studies/30706293/1/files/59830674.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4416627366.pdf","grobid_xml":"https://content.openalex.org/works/W4416627366.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4361954344","https://openalex.org/W4306247913","https://openalex.org/W2793886497","https://openalex.org/W3134351387","https://openalex.org/W3213571904","https://openalex.org/W2907846619","https://openalex.org/W4417016048","https://openalex.org/W4390984994","https://openalex.org/W4409631197","https://openalex.org/W4409831583"],"abstract_inverted_index":{"Supplementary":[0],"Table":[1],"1.":[2],"Clinical":[3],"characteristics":[4],"of":[5],"patients":[6],"with":[7],"relapsed":[8],"or":[9],"refractory":[10],"acute":[11],"myeloid":[12],"leukemia.":[13]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2025-11-25T00:00:00"}